Calamos Advisors LLC Acquires 314 Shares of Johnson & Johnson $JNJ

Calamos Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 570,762 shares of the company’s stock after purchasing an additional 314 shares during the period. Calamos Advisors LLC’s holdings in Johnson & Johnson were worth $87,184,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Nuveen LLC bought a new stake in Johnson & Johnson in the first quarter valued at $1,369,188,000. Pacer Advisors Inc. boosted its stake in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after buying an additional 2,557,388 shares during the period. Kingstone Capital Partners Texas LLC bought a new position in Johnson & Johnson in the second quarter worth about $401,420,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Johnson & Johnson by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock worth $2,803,042,000 after buying an additional 2,129,612 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on JNJ shares. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Loop Capital set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Price Performance

JNJ opened at $194.52 on Thursday. The firm has a market cap of $468.65 billion, a PE ratio of 18.78, a P/E/G ratio of 2.19 and a beta of 0.38. The stock has a 50-day moving average price of $185.13 and a 200-day moving average price of $169.48. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $195.55. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.